Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Autografts Clear all
Terminated Phase 1Phase 2 Interventional Results available

StrataGraft Overlay of Meshed Autograft in Full-thickness Thermal Burns

NCT04765202
View directory record Official record
Conditions
Full Thickness Thermal Burn
Interventions
AG Tx, SOMA Tx
Procedure · Biological
Lead sponsor
Stratatech, a Mallinckrodt Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Jul 23, 2026, 6:09 AM EDT
Completed Not applicable Interventional Results available

Prevention of Oral Mucositis Using Photobiomodulation Therapy

NCT04227340
View directory record Official record
Conditions
Oral Mucositis
Interventions
Photobiomodulation Therapy (PBM), Pain and Oral Function Assessment, Parent-Reported Satisfaction Survey
Device · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Jul 23, 2026, 6:09 AM EDT
Completed Phase 2 Interventional Results available

High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma

NCT00349778
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cyclophosphamide, Etoposide, Melphalan, Carmustine, Filgrastim
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Jul 23, 2026, 6:09 AM EDT
Completed Phase 2 Interventional

Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma

NCT00005985
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, carmustine, cyclophosphamide, cytarabine, dexamethasone, etoposide, mitoxantrone hydrochloride, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 70 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Jul 23, 2026, 6:09 AM EDT
No Longer Available No phase listed Expanded access

Emergent Expanded Access for ahSC Augmentation of Nerve Autografts After Severe Peripheral Nerve Injury.

NCT02510079
View directory record Official record
Conditions
Sciatic Nerve Injury
Interventions
Autologous human Schwann cells
Biological
Lead sponsor
W. Dalton Dietrich
Other
Eligibility
18 Years to 65 Years · Female only
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Jul 23, 2026, 6:09 AM EDT
Completed Not applicable Interventional

Post Marketing Study of MagnetOs Putty Compared to Local Autograft in Patients Undergoing Posterolateral Lumbar Fusion

NCT04679896
View directory record Official record
Conditions
Degenerative Disc Disease, Spine Fusion
Interventions
MagnetOs Putty
Device
Lead sponsor
Kuros Biosurgery AG
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Paducah, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Jul 23, 2026, 6:09 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Autologous CD34+ Hematopoietic Stem Cells Transduced ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Lentiviral Vector Encoding for the Human ADA Gene

NCT01852071
View directory record Official record
Conditions
ADA-SCID
Interventions
Infusion of autologous EFS-ADA LV CD34+ (OTL-101), busulfan, PEG-ADA ERT
Genetic · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
1 Month to 17 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Los Angeles, California • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Jul 23, 2026, 6:09 AM EDT
Completed Phase 2 Interventional Results available

GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma

NCT00521014
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, rituximab, sargramostim, carmustine, cytarabine, etoposide, melphalan, autologous hematopoietic stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Jul 23, 2026, 6:09 AM EDT
Completed Not applicable Interventional

Salivary Gland Autotransplantation for Treatment of XRT Induced Xerostomia

NCT04007081
View directory record Official record
Conditions
Xerostomia, Head and Neck Cancer
Interventions
Bone Marrow Aspiration, Ultrasound Imaging of Salivary Glands, Salivary Assay, Quality of Life Instruments
Procedure · Diagnostic Test · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 89 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Jul 23, 2026, 6:09 AM EDT
Terminated Phase 1 Interventional

A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation

NCT00672152
View directory record Official record
Conditions
Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS), B Cell Malignancies
Interventions
WT1 derived peptides
Biological
Lead sponsor
Michael Morse, MD
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 9, 2013 · Synced Jul 23, 2026, 6:09 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Auto Transplantation of Wisdom Teeth

NCT06553300
View directory record Official record
Conditions
Autotransplantation of Wisdom Teeth, Patelet Rich Fibrin
Interventions
Autotransplantation with PRF, Autotransplatation Only
Procedure
Lead sponsor
Cleveland Dental Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Jul 23, 2026, 6:09 AM EDT
Completed Phase 2 Interventional

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

NCT00003402
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
carmustine, cisplatin, cyclophosphamide, dexamethasone, etoposide, melphalan, paclitaxel, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2019 · Synced Jul 23, 2026, 6:09 AM EDT
Completed Phase 3 Interventional Results available

Two Different Methods of Collecting Stem Cells For an Autologous Stem Cell Transplant in Treating Patients With Diffuse Large Cell Lymphoma

NCT00566228
View directory record Official record
Conditions
Lymphoma
Interventions
autologous hematopoietic stem cell transplantation, leukapheresis
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 8, 2018 · Synced Jul 23, 2026, 6:09 AM EDT
Completed No phase listed Observational

A Prospective Study of Instrumented, Posterolateral Lumbar Fusions (PLF) With OsteoAMP®

NCT02225444
View directory record Official record
Conditions
Spondylolisthesis, Scoliosis, Intervertebral Disc Disease
Interventions
OsteoAMP
Other
Lead sponsor
Bioventus LLC
Industry
Eligibility
21 Years to 85 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
9
States / cities
New Haven, Connecticut • Chicago, Illinois • Kansas City, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Jul 23, 2026, 6:09 AM EDT
Not yet recruiting Not applicable Interventional

Free Soft Tissue Grafts FSTG) Using Autograft Palatal Donor Tissue vs. Xenograft Collagen Matrix (Zderm™)

NCT07713199
View directory record Official record
Conditions
Gingival Recession Localized Moderate, Dental Implant
Interventions
Zderm
Device
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 89 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 23, 2026, 6:09 AM EDT
Completed Phase 2 Interventional

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma

NCT00003399
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
carmustine, cisplatin, cyclophosphamide, dexamethasone, etoposide, melphalan, paclitaxel, in vitro-treated peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2019 · Synced Jul 23, 2026, 6:09 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation

NCT02112045
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Granix, High dose melphalan (HDR), Autologous Stem Cell Transplant (ASCT)
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Jul 23, 2026, 6:09 AM EDT
Completed Phase 1 Interventional

Combination Stem Cell Therapy for the Treatment of Severe Leg Ischemia

NCT00518401
View directory record Official record
Conditions
Critical Limb Ischemia, Peripheral Vascular Disease
Interventions
Mesendo
Biological
Lead sponsor
TCA Cellular Therapy
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Covington, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 27, 2011 · Synced Jul 23, 2026, 6:09 AM EDT
Completed Phase 2 Interventional

Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation

NCT01339572
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Multiple Myeloma
Interventions
Plerixafor, Filgrastim
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Jul 23, 2026, 6:09 AM EDT
Terminated Phase 3 Interventional Results available

Opioid Use in Single Shot Nerve Block vs Continuous Peripheral Nerve Infusion in Anterior Cruciate Ligament (ACL) Repair

NCT02075411
View directory record Official record
Conditions
Injury of Anterior Cruciate Ligament
Interventions
bupivacaine, continuous perineural infusion catheter
Drug · Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
14 Years to 18 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Jul 23, 2026, 6:09 AM EDT
Enrolling by invitation No phase listed Observational

Blood Flow Restriction Following ACLR w/Quad Autograft

NCT06636045
View directory record Official record
Conditions
Autografts, Blood Flow Restriction Therapy, Rehabilitation Outcome, Quadriceps Muscle Strength, Anterior Cruciate Ligament Reconstruction
Interventions
Not applicable- observational study
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
14 Years to 40 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Jul 23, 2026, 6:09 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

NCT02353572
View directory record Official record
Conditions
Plasma Cell Myeloma, Plasmacytosis, Recurrent Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma
Interventions
Melphalan, Bortezomib, Dexamethasone, Autologous Transplant
Drug · Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 8, 2015 · Synced Jul 23, 2026, 6:09 AM EDT
Withdrawn Phase 2 Interventional

Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid Leukemia

NCT03515707
View directory record Official record
Conditions
Acute Myeloid Leukemia, Minimal Residual Disease Negativity
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Etoposide, Laboratory Biomarker Analysis
Procedure · Drug · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 69 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 31, 2021 · Synced Jul 23, 2026, 6:09 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of OMS103HP in Patients Undergoing Autograft Anterior Cruciate Ligament (ACL) Reconstruction

NCT00226772
View directory record Official record
Conditions
Knee Injuries
Interventions
OMS103HP, Vehicle
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
15 Years to 65 Years
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
15
States / cities
Encinitas, California • Denver, Colorado • Englewood, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Jul 23, 2026, 6:09 AM EDT